Biogened S.A.

BGD

PLBIOGN00018

Pharmaceuticals

End-of-day quote Warsaw S.E. Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
18 ^PLN	+0.56%		-11.76%	-.--%

05-15	Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-14	Biogened S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Biogened S.A. announced that it expects to receive PLN 6 million in funding

June 19, 2016

Biogened S.A. (WSE:BGD) announced a private placement of up to 400,000 series I shares at a price of PLN 15 per share for gross proceeds of PLN 6,000,000 on June 20, 2016.

Latest news about Biogened S.A.

Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Biogened S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-14	CI
Biogened S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Biogened S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Biogened S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-14	CI
Biogened S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-14	CI
Biogened S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Biogened S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Biogened S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-14	CI
Biogened S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-14	CI
Biogened S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Biogened S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI
Biogened S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-02-12	CI
Biogened S.A. Announces Dividend, Payable on November 11, 2020	20-07-29	CI
Biogened S.A. Receives FDA Approval for Vumerity for Multiple Sclerosis	19-11-10	CI
Biogened S.A. announced that it expects to receive PLN 0.5 million in funding	17-05-18	CI
Biogened S.A. announced that it has received PLN 3 million in funding	16-11-28	CI
Biogened S.A. announced that it expects to receive PLN 6 million in funding	16-06-19	CI
Enrav Fizan acquired 32.2% stake in Biogened S.A..	16-03-01	CI
Bioniq Limited acquired additional 6.96% stake in Biogened S.A..	16-02-23	CI
LAVINIA I Sp. z o.o. Sp. k. acquired additional 4.86% stake in Biogened S.A..	16-02-23	CI
Biogened S.A. announced that it expects to receive PLN 5 million in funding.	15-06-14	CI

Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Companyâs product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
BIOGENED S.A.	-.--%	11.22M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B